Agarikon

Cultivated Laricifomes officinalis mycelium contains 5-hydroxytryptophan (5-HTP), the immediate precursor of serotonin, at concentrations of approximately 518 mg per 100 g dry weight. Concurrent administration with SSRIs floods serotonergic synapses with substrate while reuptake is blocked, elevating risk of serotonin syndrome (agitation, hyperthermia, clonus, autonomic instability). The reaction is analogous to the well-documented 5-HTP + SSRI contraindication.

Avoid concurrent use of Agarikon mycelium products with SSRIs, SNRIs, tricyclic antidepressants, trazodone, or tramadol. If unavoidable, use only fruiting body extracts (lower 5-HTP content) and monitor closely for early serotonin syndrome symptoms. Refer to emergency department for tachycardia, agitation, hyperreflexia, or hyperthermia.

Agarikon mycelium's high 5-HTP content (~518 mg/100g dry weight) combined with MAO inhibition prevents serotonin degradation, producing markedly elevated CNS serotonin concentrations. This combination carries potential for life-threatening serotonin syndrome and hypertensive crisis, parallel to the absolute MAOI contraindication with 5-HTP supplements and tryptophan.

Absolute contraindication with phenelzine, tranylcypromine, selegiline, moclobemide, and linezolid (weak MAOI). Washout period of at least 2 weeks between Agarikon discontinuation and MAOI initiation. Patient education should specifically name Agarikon/Laricifomes officinalis/Fomitopsis officinalis as an MAOI interaction risk.

Officimalonic acids I-O isolated from L. officinalis fruiting bodies inhibit COX-2 enzyme activity and suppress nitric oxide production in macrophage inflammation models. Additive COX-2 inhibition with celecoxib or other coxibs may enhance anti-inflammatory effect but theoretically could compound gastrointestinal, renal, or cardiovascular COX-2 related adverse effects at high extract doses.

Generally mild interaction. Routine monitoring of renal function and blood pressure in patients using extract doses long-term with NSAIDs. No dose adjustment ordinarily required at typical supplemental doses (<1 g/day).

Two chlorinated coumarins unique to L. officinalis (2H-6-chloro-2-oxo-4-phenyl-1-benzopyran-3-carboxylic acid ethyl ester and 6-chloro-4-phenyl-coumarin) exhibit direct activity against both replicating and non-replicating Mycobacterium tuberculosis. Combined with first-line antitubercular drugs, additive antimycobacterial effect is plausible, but hepatotoxicity risk compounds (both isoniazid and agarikon extracts carry reports of hepatic injury).

If used in adjunctive treatment of drug-resistant TB, monitor liver enzymes (ALT/AST) monthly given additive hepatotoxicity potential. Not a substitute for standard multi-drug therapy. Patient should inform TB clinician of any Agarikon use.

Agarikon extracts stimulate innate immunity via beta-glucan activation of Dectin-1 receptors and macrophage/NK cell activity, plus enhance antiviral immune response against herpes, influenza A/B, and variola viruses. This pharmacodynamic immune stimulation directly opposes tacrolimus-mediated calcineurin inhibition and may precipitate acute rejection in solid organ transplant recipients.

Avoid in kidney, liver, heart, lung transplant recipients and patients on tacrolimus for autoimmune disease. Counsel that immune-stimulating polypore supplements including ShieldsUp! blends should be disclosed to transplant team. Monitor tacrolimus trough levels more frequently if unavoidable.